Xeris Biopharma (XERS) Stock Forecast & Price Target $3.57 +0.02 (+0.56%) Closing price 04:00 PM EasternExtended Trading$3.56 0.00 (-0.14%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Xeris Biopharma - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 4 Analyst RatingsSell0Hold1Buy3 Based on 4 Wall Street analysts who have issued ratings for Xeris Biopharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for XERS. Consensus Price Target $5.1544.26% Upside According to the 4 analysts' twelve-month price targets for Xeris Biopharma, the average price target is $5.15. The highest price target for XERS is $6.60, while the lowest price target for XERS is $3.00. The average price target represents a forecasted upside of 44.26% from the current price of $3.57. Get the Latest News and Ratings for XERS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors. Enter your email to sign up for newsletter Sign Up XERS Analyst Ratings Over TimeTypeCurrent Forecast2/11/24 to 2/10/251 Month Ago1/12/24 to 1/11/253 Months Ago11/13/23 to 11/12/241 Year Ago2/11/23 to 2/11/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)2 Buy rating(s)2 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$5.15$4.87$4.87$4.67Forecasted Upside44.26% Upside43.14% Upside54.50% Upside62.60% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy XERS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History XERS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Xeris Biopharma Stock vs. The CompetitionTypeXeris BiopharmaMedical CompaniesS&P 500Consensus Rating Score 2.75 2.82 2.53Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside44.26% Upside27,376.76% Upside13.56% UpsideNews Sentiment RatingNeutral NewsSee Recent XERS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails1/29/2025Jefferies Financial Group2 of 5 starsGlen SantangeloSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $6.00+63.89%11/11/2024HC Wainwright2 of 5 stars Boost TargetBuy ➝ Buy$6.00 ➝ $6.60+98.20%11/11/2024Piper Sandler2 of 5 stars DowngradeOverweight ➝ Neutral$3.00 ➝ $3.00-13.54%3/28/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$5.00+145.10%8/28/2023Craig HallumSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$4.50+109.30%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:13 PM ET. XERS Forecast - Frequently Asked Questions What is Xeris Biopharma's forecast for 2025? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Xeris Biopharma is $5.15, with a high forecast of $6.60 and a low forecast of $3.00. Should I buy or sell Xeris Biopharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" XERS shares. Does Xeris Biopharma's stock price have much upside? According to analysts, Xeris Biopharma's stock has a predicted upside of 44.26% based on their 12-month stock forecasts. What analysts cover Xeris Biopharma? Xeris Biopharma has been rated by research analysts at Jefferies Financial Group in the past 90 days. Do Wall Street analysts like Xeris Biopharma more than its competitors? Analysts like Xeris Biopharma less than other "medical" companies. The consensus rating score for Xeris Biopharma is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how XERS compares to other companies. Stock Forecasts and Research Tools Related Companies BEAM Stock Forecast TARS Stock Forecast IDYA Stock Forecast NAMS Stock Forecast AGIO Stock Forecast APGE Stock Forecast WVE Stock Forecast SDGR Stock Forecast BLTE Stock Forecast IOVA Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:XERS) was last updated on 2/10/2025 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | SponsoredBill O’Reilly: “the best-prepared president in history.”"We're going to bring back the American Dream... bigger, better, bolder, richer, safer, and stronger than ever...The Oxford Club | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XERS Stock Alerts